Across TCGA pan-cancer cohorts, MAPRE3-AS1 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MAPRE3-AS1 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MAPRE3-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPRE3-AS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KICH show a favorable association.
KIRC, LIHC, and STAD are the cancer types where MAPRE3-AS1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.